Could a simple blood test stop cancer patients from quitting treatment?
NCT ID NCT07465172
Summary
This study aims to find out if measuring a hormone in the blood (GDF-15) can help predict which breast cancer patients will experience severe nausea, vomiting, or weight loss from the drug T-DXd. Researchers will follow 150 patients with advanced breast cancer who are starting T-DXd treatment. The goal is to gather knowledge that could lead to better ways to manage these difficult side effects in the future.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Lake Macquarie Private Hospital
Newcastle, New South Wales, 2290, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Okayama University Hospital
Okayama, 700-8558, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Peter MacCallum Cancer Centre
Melbourne, Victoria, 3000, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.